Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The architect of Iran’s military survival remains defiant - 2In the background: Visiting Notable Film Areas All over the Planet
- 3What's changing about healthcare in 2026 — Medicare, Medicaid, ACA, premiums, and enrollment deadlines
- 412 times rockets and spacecraft crashed and burned in 2025
- 5IDF finds weapon of slain hostage Capt. Daniel Perez in booby-trapped Gaza compound
- The Benefits of Effective money management for Your Youngsters' Future Monetary Prosperity
- Five EU states press for windfall taxes on fossil energy sector
- The Best 15 Applications for Efficiency and Association
- UN chief warns he could refer Israel to ICJ over laws targetting UNRWA
- Top 15 Style Creators Changing the Business
- Airport wait times won't return to normal until Congress reaches a deal to pay TSA. Here's why they still can't come to an agreement.
- Trouvez La Carte De Cr\u00e9dit Id\u00e9ale Pour Vos Besoins En Belgique
- What's your #1 tone
- How to see the Ursids, the final meteor shower of 2025
